Guardant Health launched its Shield multi‑cancer detection (MCD) test into broader clinical use and signaled plans to gather real‑world adoption data for multi-cancer screening, while Diasorin secured FDA 510(k) clearance for a multiplex respiratory PCR kit that detects SARS‑CoV‑2, influenza A/B and RSV plus RSV differentiation—broadening point-of-care and lab testing options. Guardant’s move reflects the growing commercial push for blood-based multi-cancer screening in colorectal and other cancers; real‑world rollout will be watched for clinical uptake and reimbursement. Diasorin’s clearance simplifies sample workflows and expands available triage tools for respiratory pathogens, important for seasonal surge planning. Both items show diagnostics firms advancing technologies that shift screening and early detection into routine practice, influencing clinical workflows and payer evaluation frameworks.